Keros Therapeutics (KROS) is experiencing a notable rise in its stock price following a significant development from Wells Fargo. The investment bank raised its price target for Keros Therapeutics by $17, signaling increased confidence in the company's future prospects. This adjustment comes amid ongoing developments in Keros' clinical trials, particularly the TROPOS trial, which is evaluating the efficacy of cibotercept in treating pulmonary arterial hypertension. Despite recent challenges, including the voluntary halting of higher-dose treatment arms due to safety concerns, the market appears optimistic about the company's potential.
Keros Therapeutics' stock is currently trading at $19.75, reflecting a 7.16% increase from its previous close of $18.43. The stock opened at $18.76 and has seen a 5.28% rise since then.